SEARCH:   Advanced

Blood, 1 May 2006, Vol. 107, No. 9, pp. 3474-3480. Prepublished online as a Blood First Edition Paper on January 5, 2006; DOI 10.1182/blood-2005-09-3869. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-09-3869v1 107/9/3474    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Garban, F. Articles by Moreau, P. Search for Related Content PubMed PubMed Citation Articles by Garban, F. Articles by Moreau, P. Related Collections Transplantation Free Research Articles Clinical Trials and Observations Neoplasia Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma Frederic Garban, Michel Attal, Mauricette Michallet, Cyrille Hulin, Jean H. Bourhis, Ibrahim Yakoub-Agha, Thierry Lamy, Gerald Marit, Frederic Maloisel, Christian Berthou, Mamoun Dib, Denis Caillot, Bernard dePrijck, Nicolas Ketterer, Jean-Luc Harousseau, Jean-Jacques Sotto, Philippe Moreau, for the Intergroupe Francophone du Myélome and the Swiss Group for Clinical Cancer Research From the University Hospital, Grenoble; University Hospital, Toulouse; University Hospital, Lyon; University Hospital, Nancy; Institut Gustave-Roussy, Paris; University Hospital, Lille; University Hospital, Rennes; University Hospital, Bordeaux; University Hospital, Strasbourg; University Hospital, Brest; University Hospital, Angers; University Hospital, Dijon; University Hospital, Nantes, France; University Hospital, Liège, Belgium; and University Hospital, Lausanne, Switzerland. The Intergroupe Francophone du Myélome (IFM) initiated 2 trials in 1999 to study patients with high-risk (2-microglobulin level greater than 3 mg/L and chromosome 13 deletion at diagnosis) de novo multiple myeloma. In both protocols, the induction regimen consisted of vincristine, doxorubicin, and dexamethasone (VAD) followed by first autologous stem cell transplantation (ASCT) prepared by melphalan 200 mg/m2. Patients with an HLA-identical sibling donor were subsequently treated with dose-reduced allogeneic stem cell transplantation (IFM99-03 trial), and patients without an HLA-identical sibling donor were randomly assigned to undergo second ASCT prepared by melphalan 220 mg/m2 and 160 mg dexamethasone with or without anti–IL-6 monoclonal antibody (IFM99-04 protocol). Two hundred eighty-four patients—65 in the IFM99-03 trial and 219 in the IFM99-04 trial—were prospectively treated and received at least one course of VAD. On an intent-to-treat basis, overall survival (OS) and event-free survival (EFS) did not differ significantly in the studies (medians 35 and 25 months in the IFM99-03 trial vs 41 and 30 months in the IFM99-04 trial, respectively). With a median follow-up time of 24 months, the EFS of the 166 patients randomly assigned in the tandem ASCT protocol was similar to the EFS of the 46 patients who underwent the entire IFM99-03 program (median, 35 vs 31.7 months), with a trend for a better OS in patients treated with tandem ASCT (median, 47.2 vs 35 months; P = .07). In patients with high-risk de novo MM, the combination of ASCT followed by dose-reduced allogeneic transplantation was not superior to tandem dose–intensified, melphalan-based ASCT. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: No RIC in high-risk myeloma? Henk Lokhorst Blood 2006 107: 3420-3421. [Full Text] [PDF] This article has been cited by other articles: J. San-Miguel, J.-L. Harousseau, D. Joshua, and K. C. Anderson Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents J. Clin. Oncol., June 1, 2008; 26(16): 2761 - 2766. [Abstract] [Full Text] [PDF] R. A. Kyle and S. V. Rajkumar Multiple myeloma Blood, March 15, 2008; 111(6): 2962 - 2972. [Abstract] [Full Text] [PDF] J. El-Cheikh, M. Michallet, A. Nagler, H. de Lavallade, F. E. Nicolini, A. Shimoni, C. Faucher, M. Sobh, D. Revesz, I. Hardan, et al. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma Haematologica, March 1, 2008; 93(3): 455 - 458. [Abstract] [Full Text] [PDF] W. Bensinger Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Drugs J. Clin. Oncol., January 20, 2008; 26(3): 480 - 492. [Abstract] [Full Text] [PDF] J.-P. Fermand Initial Therapy for Multiple Myeloma: Role of Stem Cell Transplantation ASCO Educational Book, January 1, 2008; 2008(1): 375 - 379. [Abstract] [Full Text] [PDF] J. A. Katzel, P. Hari, and D. H. Vesole Multiple Myeloma: Charging Toward a Bright Future CA Cancer J Clin, September 1, 2007; 57(5): 301 - 318. [Abstract] [Full Text] [PDF] F. van Rhee, J. Crowley, B. Barlogie, S. V. Rajkumar, R. A. Kyle, P. Moreau, J.-L. Harousseau, M. Attal, B. Bruno, G. Ciccone, et al. Allografting or Autografting for Myeloma N. Engl. J. Med., June 21, 2007; 356(25): 2646 - 2648. [Full Text] [PDF] M. Cavo Nonmyeloablative allotransplantation for myeloma: light and shade Blood, April 15, 2007; 109(8): 3134 - 3135. [Full Text] [PDF] H. Avet-Loiseau, M. Attal, P. Moreau, C. Charbonnel, F. Garban, C. Hulin, S. Leyvraz, M. Michallet, I. Yakoub-Agha, L. Garderet, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome Blood, April 15, 2007; 109(8): 3489 - 3495. [Abstract] [Full Text] [PDF] B. Bruno, M. Rotta, F. Patriarca, N. Mordini, B. Allione, F. Carnevale-Schianca, L. Giaccone, R. Sorasio, P. Omede, I. Baldi, et al. A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma N. Engl. J. Med., March 15, 2007; 356(11): 1110 - 1120. [Abstract] [Full Text] [PDF] J. H. Antin Reduced-Intensity Stem Cell Transplantation: "...whereof a little More than a little is by much too much." King Henry IV, part 1, I, 2 Hematology, January 1, 2007; 2007(1): 47 - 54. [Abstract] [Full Text] [PDF] R. Fonseca Strategies for Risk-Adapted Therapy in Myeloma Hematology, January 1, 2007; 2007(1): 304 - 310. [Abstract] [Full Text] [PDF] M. Attal, P. Moreau, H. Avet-Loiseau, and J.-L. Harousseau Stem Cell Transplantation in Multiple Myeloma Hematology, January 1, 2007; 2007(1): 311 - 316. [Abstract] [Full Text] [PDF] K.-S. Eom, C.-K. Min, S. Lee, Y.-J. Kim, S.-Y. Kim, H.-J. Kim, J.-W. Lee, W.-S. Min, and C.-C. Kim Efficacy of Up-Front Treatment with a Double Stem Cell Transplantation in Multiple Myeloma Jpn. J. Clin. Oncol., July 1, 2006; 36(7): 432 - 438. [Abstract] [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020